US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.
A group of leading scientists have urged Pfizer to wait until at least late November before asking for the FDA to authorise its potential COVID-19 vaccine, to double-check its safety.
